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1. INTRODUCTION {#cas14449-sec-0001}
===============

The NCCN recommends sunitinib, pazopanib, cabozantinib, nivolumab plus ipilimumab, or axitinib plus pembrolizumab as first‐line treatments for advanced or metastatic renal cell carcinoma.[^1^](#cas14449-bib-0001){ref-type="ref"} However, almost all patients eventually become resistant to these drugs and show progression during first‐line treatment. The recommended postprogression treatment options include axitinib, nivolumab, and more recently, cabozantinib, and lenvatinib plus everolimus.[^1^](#cas14449-bib-0001){ref-type="ref"}, [^2^](#cas14449-bib-0002){ref-type="ref"} Although there are several subsequent therapy options, the information regarding their comparative effectiveness is limited due to a lack of head‐to‐head comparisons of the efficacy of these drugs against advanced or metastatic kidney cancer after the failure of first‐line therapy.

Axitinib, a selective TKI of VEGFR‐1, ‐2, and ‐3, has been accepted as one of the subsequent treatment options for patients with advanced renal cell carcinoma that have previously been treated with systemic therapy since the pivotal phase III study AXIS trial.[^3^](#cas14449-bib-0003){ref-type="ref"} The AXIS trial showed that axitinib was more effective than sorafenib against metastatic renal cell carcinoma in the second‐line setting (PFS, 6.7 vs 4.7 months; hazard ratio, 0.67; *P* \< .001). Although the AXIS trial and other registrational studies[^3^](#cas14449-bib-0003){ref-type="ref"}, [^4^](#cas14449-bib-0004){ref-type="ref"}, [^5^](#cas14449-bib-0005){ref-type="ref"} established the efficacy and safety of axitinib as a subsequent therapy for metastatic renal cell carcinoma, data regarding its real‐world use in the second‐ or third‐line treatment setting are still limited.[^6^](#cas14449-bib-0006){ref-type="ref"}, [^7^](#cas14449-bib-0007){ref-type="ref"}, [^8^](#cas14449-bib-0008){ref-type="ref"}, [^9^](#cas14449-bib-0009){ref-type="ref"} Recently, immune checkpoint inhibitors, such as programmed cell death‐1 Ab, have become promising treatment options. Although this immunotherapy drug induces a durable response in some patients, it is sometimes associated with severe irreversible immune‐related AEs.[^10^](#cas14449-bib-0010){ref-type="ref"} Therefore, the safety of axitinib and its ability to achieve prolonged PFS as a subsequent treatment for metastatic renal cell carcinoma suggest that it could be an important drug, especially if it was given to appropriately selected patients who could expect to achieve long survival. In these circumstances, we could save other effective treatment options, such as immune checkpoint inhibitors, for subsequent, and possibly extended, phases of treatment. From this point of view, there are still unmet needs with regard to the data available about the post‐VEGFR‐TKI monotherapy treatment outcomes of kidney cancer patients from outside of clinical trials, which would help clinicians to choose appropriate patients who could expect to derive benefit from axitinib therapy.

Until now, IMDC models[^11^](#cas14449-bib-0011){ref-type="ref"} have been used to allocate patients who were scheduled to receive second‐line treatment into favorable, intermediate, and poor risk groups in randomized clinical trials. However, there are several weaknesses with the risk classification system. As for the IMDC model, it was originally developed for patients that were treated with first‐line therapy,[^12^](#cas14449-bib-0012){ref-type="ref"} although it was recently validated for those receiving second‐line treatment.[^11^](#cas14449-bib-0011){ref-type="ref"} Due to the lack of effective predictive markers for choosing appropriate subsequent treatments for kidney cancer,[^13^](#cas14449-bib-0013){ref-type="ref"} physicians need other clinical guides so that they can ensure that patients will really benefit from the selected therapy.

The first aim of the present study was to evaluate the efficacy of the real‐world use of axitinib as a second‐ or third‐line therapy in a Japanese multicenter cohort. Second, we sought to identify pretreatment clinical factors that could affect the prognosis of previously treated metastatic renal cell carcinoma patients. Finally, we aimed to develop and validate a prognostic model that could be used to stratify such patients into appropriate risk groups and identify those patients who could derive a long‐term benefit from axitinib therapy.

2. MATERIALS AND METHODS {#cas14449-sec-0002}
========================

2.1. Patients {#cas14449-sec-0003}
-------------

We undertook a retrospective, descriptive study to evaluate the efficacy of axitinib in patients with metastatic renal cell carcinoma that had previously been treated with 1 or 2 VEGFR‐TKI regimens at 1 of 36 university, public, or private hospitals belonging to the Japan Urologic Oncology Group between January 2012 and February 2019. This study was approved by the institutional review board of each hospital. The approval number was 018‐0003 for Hokkaido University Hospital. The patients' background and survival data were retrospectively obtained from medical charts. All patients (n = 590) were aged 20 years or older, had no history of immune checkpoint inhibitor treatment, and started receiving axitinib between January 2012 and December 2016. In addition, we excluded cases without a pathological diagnosis (n = 43) or in which the axitinib treatment period was less than 4 weeks (n = 49). The detailed reasons for discontinuation and any subsequent treatments are shown in Table [S1](#cas14449-sup-0002){ref-type="supplementary-material"}. Of the remaining 498 patients, 13 patients for whom detailed data were missing were also excluded. In total, 485 patients were analyzed in the final cohort. The patient flow is described in Figure [1](#cas14449-fig-0001){ref-type="fig"}.

![Patient flow diagram for the present study of a multicenter cohort treated with axitinib for metastatic renal cell carcinoma. TKI, tyrosine kinase inhibitor; VEGFR, vascular endothelial growth factor receptor.](CAS-111-2460-g001){#cas14449-fig-0001}

Axitinib was prescribed as recommended, with a starting dose of 5 mg twice daily (10 mg/d).[^3^](#cas14449-bib-0003){ref-type="ref"} Dose titration was allowed if a patient tolerated the standard dose without suffering AEs. When a patient suffered from an intolerable AE, dose reduction was considered based on the severity of the AE. The severity of AEs was defined based on the Common Terminology Criteria for Adverse Events version 5.0. Among the AEs related to axitinib, those that led to dose reduction or treatment interruption were retrieved during the medical chart review.

As a baseline assessment, patient performance and laboratory data that were obtained just before the start of the axitinib therapy were collected. Laboratory data related to the IMDC[^12^](#cas14449-bib-0012){ref-type="ref"} system were standardized according to the institutional ULN and LLN. The patients were generally followed up with physical examinations and routine blood tests every 2‐4 weeks. Radiographic CT assessments were generally carried out every 3 months, whereas bone scans were not routinely scheduled, but were carried out when clinically indicated. The tumor response was recorded as the best response, that is, a CR, PR, SD, or PD, seen during treatment, according to RECIST version 1.1.[^14^](#cas14449-bib-0014){ref-type="ref"} The ORR was defined as the percentage of cases that showed a PR or CR during the treatment assessment.

The primary outcome was the OS of metastatic renal cell carcinoma patients that were treated with axitinib after 1 or 2 VEGFR‐TKI regimens before the immunotherapy era, which is consistent with the Checkmate 025 study. In addition, we also investigated potential prognostic factors for predicting OS in this cohort (sex, age, disease stage at diagnosis, prior nephrectomy, histology, sarcomatoid features, the number of metastatic sites at the start of axitinib therapy, time interval from initial diagnosis, the number of previous lines of TKI treatment received before axitinib, the total duration of prior TKI treatment, Karnofsky PS, the neutrophil : lymphocyte ratio, a low hemoglobin level \[less than LLN\], a high platelet count \[greater than ULN\], the serum albumin level, a high calcium level, a high serum LDH level \[\>1.5× ULN\], and the CRP level). The cut‐off value for the neutrophil : lymphocyte ratio, the serum albumin level, and the CRP level were set as their median values. Overall survival was defined as the time from the start of the axitinib therapy to death from any cause. Regarding the calculation of OS, patients that were treated with nivolumab as a subsequent therapy were censored at the time when nivolumab was administered. The reason for this is that we intended to focus on the clinical outcomes of the patients who received molecular targeted therapy before the introduction of IO drugs. Progression‐free survival was defined as the time from the start of the axitinib therapy to the first documentation of progression or death. For each outcome, patients with no events of interest were also censored at the date of their last outpatient visit.

2.2. Statistical analysis {#cas14449-sec-0004}
-------------------------

The details of the patients' baseline characteristics, responses to treatment, and AEs were analyzed. Categorical variables are shown as percentages. Continuous variables are presented as median and interquartile range values. Overall survival and PFS were estimated using the Kaplan‐Meier method. We used 4‐week landmark survival analysis to remove the bias introduced by patients whose treatment periods were too short. In the exploratory analyses, we evaluated the associations between the patients' characteristics before administration of axitinib therapy (IMDC risk group \[poor, intermediate, or favorable\]) and OS.

A total of 485 patients were randomly assigned to the model‐development set (n = 242) or the validation set (n = 243) at a 1:1 ratio using a random number generator. First, we undertook univariate analyses of each variable using Cox's model. Then we chose variables that showed *P* values of less than .10 in the univariate analyses as candidates for the multivariate model. We undertook a multivariate analysis with the candidate variables, and the variables that displayed *P* values of less than .05 were selected as independent predictors of OS. Risk scores for the selected variables were then calculated for the patients in the model‐development set, who were categorized based on their total scores as favorable, intermediate, or poor risk. Kaplan‐Meier survival curves were then calculated for each risk category. Finally, the patients in the validation set were categorized into risk groups based on our new risk model. Comparisons of our model with the IMDC risk model and MSKCC risk model for second‐line treatment, respectively, were undertaken using the same steps as were used in our validation process. The ability of our model to predict OS was compared with that of the IMDC model by evaluating the AUC values of time‐dependent ROC curves of the prognostic abilities of the predictive models.[^15^](#cas14449-bib-0015){ref-type="ref"} The AUC values were calculated using SAS version 9.4 (SAS Institute). Other statistical analyses were undertaken using JMP version 14 (SAS Institute), and *P* values of less than .05 were considered to indicate a statistically significant difference.

The study design and reporting were carried out based on the TRIPOD statement,[^16^](#cas14449-bib-0016){ref-type="ref"}, [^17^](#cas14449-bib-0017){ref-type="ref"} and the findings of this study were reported according to the TRIPOD guidelines throughout the study period (Table [S2](#cas14449-sup-0003){ref-type="supplementary-material"}).

3. RESULTS {#cas14449-sec-0005}
==========

3.1. Patients' characteristics {#cas14449-sec-0006}
------------------------------

The patients' characteristics are shown in Table [1](#cas14449-tbl-0001){ref-type="table"}. Four hundred and eighty‐five metastatic renal cell carcinoma patients (median follow‐up time, 18.0 months \[range, 1‐72 months\]) received axitinib as a second‐ (86.8%) or third‐line (13.2%) treatment. As shown in Table [1](#cas14449-tbl-0001){ref-type="table"}, 76.7% of the patients were male, and 48.7% presented with metastatic disease at diagnosis. In total, 12.2%, 64.3%, and 19.6% were classified as favorable, intermediate, and poor risk, respectively, according to the IMDC risk model. The most prevalent histological type was clear cell carcinoma, which was present in 429 (88.5%) patients. The number of metastatic sites ranged from 1 to 6. The most common site of distant metastasis was the lungs (69.9%). Nephrectomy and metastasectomy had previously been carried out in 440 (90.7%) and 100 (22.2%) patients, respectively. The most common first‐line therapy was sunitinib (69.1%).

###### 

Characteristics of 485 patients with metastatic renal cell carcinoma treated with axitinib

  Baseline characteristics                                           Entire cohort (n = 485)   
  ------------------------------------------------------------------ ------------------------- ---------
  Age, median (IQR)                                                  67                        (61‐74)
  Gender, n (%)                                                                                
  Male                                                               372                       76.7
  Female                                                             113                       23.3
  Stage at diagnosis, n (%)                                                                    
  Localized                                                          249                       51.3
  Metastatic                                                         236                       48.7
  Risk group (IMDC), n (%)                                                                     
  Favorable                                                          59                        12.2
  Intermediate                                                       312                       64.3
  Poor                                                               95                        19.6
  NA                                                                 19                        3.9
  Prior nephrectomy, n (%)                                           440                       90.7
  Metastasectomy, n (%)                                              100                       22.2
  Histology, n (%)                                                                             
  Clear cell adenocarcinoma                                          429                       88.5
  Papillary carcinoma (type 1)                                       7                         1.4
  Papillary carcinoma (type 2)                                       19                        3.9
  Chromophobe carcinoma                                              10                        2.1
  Others                                                             20                        4.1
  Sarcomatoid feature, n (%)                                         43                        8.9
  Number of metastatic sites, n (%)                                                            
  1                                                                  216                       44.5
  2                                                                  139                       28.7
  3 or more (range, 3‐6)                                             130                       26.8
  Site of metastases, n (%)                                                                    
  Lung                                                               339                       69.9
  Liver                                                              75                        15.5
  Bone                                                               147                       30.3
  Brain                                                              23                        4.7
  Lymph node                                                         137                       28.3
  Adrenal gland                                                      27                        5.6
  Pancreas                                                           39                        8.0
  Others                                                             93                        19.2
  Less than 1 y from initial diagnosis                               29                        6.0
  Number of previous lines of TKI treatment before axitinib, n (%)                             
  1 line                                                             421                       86.8
  2 lines                                                            64                        13.2
  First‐line treatment, n (%)                                                                  
  Sorafenib                                                          115                       23.7
  Sunitinib                                                          335                       69.1
  Pazopanib                                                          35                        7.2
  Second‐line treatment, n (%)                                                                 
  Sorafenib                                                          21                        32.8
  Sunitinib                                                          34                        53.1
  Pazopanib                                                          9                         14.1
  Karnofsky performance status ≤80%                                  184                       37.9
  Neutrophil‐lymphocyte ratio \>2.3                                  224                       46.2
  Hemoglobin \< lower limit of normal                                354                       73.0
  Platelet count \> upper limit of normal                            69                        14.2
  Albumin level \<3.7 g/dL                                           208                       42.9
  Corrected calcium \> upper limit of normal                         20                        4.1
  LDH \>1.5× upper limit of normal                                   33                        6.8
  CRP level 0.7 mg/dL                                                213                       43.9

Abbreviations: CRP, C reactive protein; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; IQR, interquartile range; LDH, lactate dehydrogenase; NA, not assessed; TKI, tyrosine kinase inhibitor.
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3.2. Outcomes of patients treated with axitinib {#cas14449-sec-0007}
-----------------------------------------------

The median duration of axitinib therapy was 8 months (Table [2](#cas14449-tbl-0002){ref-type="table"}). Initially, 5 mg axitinib was given twice daily to 399 (82.2%) patients. Eighty‐three (17.1%) patients started receiving axitinib at a dose that was lower than this recommended dose, and 3 (\<1%) patients started receiving axitinib at a dose that was higher than the recommended dose. Dose escalation and reduction were carried out in 65 (13.4%) and 103 (21.2%) patients, respectively, resulting in a mean relative dose intensity of 85.2% throughout this series. At the time of the analysis, 44 patients (9.1%) were still being treated. The main reasons for treatment interruption were PD (67.6%), toxicities (26.8%), CR (2.8%), and other (2.8%). The best response was CR, PR, SD, and PD in 2.3% (n = 11), 19.8% (n = 96), 56.1% (n = 272), and 20.6% (n = 100) of cases, respectively. The median OS was 34 (95% CI, 28‐43) months, and the median PFS was 13 (95% CI, 11‐16) months (Figure [2](#cas14449-fig-0002){ref-type="fig"}). The median OS of the patients treated with axitinib after 1 and 2 VEGFR‐TKI regimens was 34 (95% CI, 28‐44) months and 31 (95% CI, 17‐50) months, respectively (*P* = .434). Table [S3](#cas14449-sup-0004){ref-type="supplementary-material"} summarizes the previously reported clinical outcomes of the patients that were treated in the subsequent treatment setting with axitinib and other promising drugs.

###### 

Treatments and clinical outcomes among 485 patients with metastatic renal cell carcinoma treated with axitinib

  Treatment                             
  ------------------------------------- ------------
  Axitinib duration (mo) median (IQR)   8 (4‐20.5)
  Dose escalation, n (%)                65 (13.4)
  Dose reduction, n (%)                 103 (21.2)
  Clinical outcomes                     
  Best response                         
  Complete response, n (%)              11 (2.3)
  Partial response, n (%)               96 (19.8)
  Stable disease, n (%)                 272 (56.1)
  Progression of disease, n (%)         100 (20.6)
  Not assessed, n (%)                   6 (1.2)
  Events                                
  PFS (months), median (95% CI)         13 (11‐16)
  OS (months), median (95% CI)          34 (28‐43)

Abbreviations: CI, confidence interval; IQR, interquartile range; OS, overall survival; PFS, progression‐free survival.
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![Kaplan‐Meier curves of overall survival (OS) and progression‐free survival (PFS) for the entire study population of patients with metastatic renal cell carcinoma treated with axitinib. The median OS was 34 (95% confidence interval \[CI\], 28‐43) months, and the median PFS was 13 (95% CI, 11‐16) months](CAS-111-2460-g002){#cas14449-fig-0002}

The treatment‐related AEs that led to dose reduction or treatment interruption are summarized in Table [S4](#cas14449-sup-0005){ref-type="supplementary-material"}. Toxicities of grade 2 or higher occurred in 227 (46.8%) patients, and toxicities of grade 3 or higher occurred in 123 (25.3%) patients. Diarrhea and fatigue were AEs that occurred in more than 10% of the 485 patients. Diarrhea (17.1%) was the most common AE grade 2 or lower. The only other common AE grade 2 or lower was fatigue (13.0%). Similarly, diarrhea (5.4%) was the most common AE grade 3 or higher. The only other common AEs grade 3 or higher was a decreased appetite (4.5%).

3.3. Development of the new ATP model {#cas14449-sec-0008}
-------------------------------------

Table [S5](#cas14449-sup-0006){ref-type="supplementary-material"} shows the baseline characteristics of all patients, the model‐development cohort, and the validation cohort. The following 9 variables showed significance in the univariate analyses (Table [3](#cas14449-tbl-0003){ref-type="table"}) and were included in the multivariate model: disease stage at diagnosis, the number of metastatic sites at the start of axitinib therapy, a high calcium level, the CRP level, a low hemoglobin level (\<LLN), the serum albumin level, the neutrophil : lymphocyte ratio, prior nephrectomy, and a Karnofsky PS of 80% or lower. Based on the multivariate analysis, 4 adverse variables (disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio) were included in the model (Table [3](#cas14449-tbl-0003){ref-type="table"}). Using these 4 prognostic factors, the model‐development cohort (n = 242) was separated into 3 risk groups. Patients with 0‐1 adverse factors were included in the favorable risk group (n = 74; 35.4%), in which the median OS was NR (95% CI, 50--NR). Patients with 2 adverse factors were included in the intermediate risk group (n = 62; 29.7%), in which the median OS was 29 (95% CI, 19‐50) months. Finally, the patients with 3‐4 adverse factors were included in the poor risk group (n = 73; 34.9%), in which the median OS was 11 (95% CI, 9‐15) months. The Kaplan‐Meier curves for these 3 risk groups are shown in Figure [3](#cas14449-fig-0003){ref-type="fig"}. Significant differences in OS (*P* \< .01) were detected among the 3 risk groups.

###### 

Univariate and multivariate analyses of overall survival 1‐mo landmark analysis with model‐development cohort of patients with metastatic renal cell carcinoma treated with axitinib (n = 242)

                                                              Univariate analysis   Multivariate analysis          
  ----------------------------------------------------------- --------------------- ----------------------- ------ -------
  Age (y)                                                                                                          
  \<67                                                        1.00                  .93                            
  [\>]{.ul}67                                                 0.98 (0.68‐1.43)                                     
  Gender                                                                                                           
  Male                                                        1.00                  .67                            
  Female                                                      1.10 (0.69‐1.69)                                     
  Stage at diagnosis                                                                                               
  Localized                                                   1.00                  *\<.01*                 1.00   \<.01
  Metastasized                                                2.68 (1.84‐3.97)      2.60 (1.61‐4.26)               
  Less than 1 y from initial diagnosis                                                                             
  No                                                          1.00                  .06                            
  Yes                                                         2.17 (0.98‐6.17)                                     
  Prior nephrectomy                                                                                                
  Yes                                                         1.00                  *\<.01*                 1.00   .12
  No                                                          3.96 (2.26‐6.53)      1.71 (0.87‐3.23)               
  Histology                                                                                                        
  Other                                                       1.00                  .50                            
  Clear cell carcinoma                                        1.27 (0.66‐2.84)                                     
  Sarcomatoid feature                                                                                              
  No                                                          1.00                  .50                            
  Yes                                                         1.27 (0.60‐2.39)                                     
  No. of metastatic sites at the time of axitinib therapy                                                          
  1                                                           1.00                  *\<.01*                 1.00   .01
  2 or more                                                   2.26 (1.53‐3.42)      1.82 (1.11‐3.05)               
  Number of previous lines of TKI treatment before axitinib                                                        
  1 line                                                      1.00                  .16                            
  2 lines                                                     1.45 (0.86‐2.32)                                     
  Total duration of prior TKI treatment                                                                            
  [\>]{.ul}7                                                  1.00                  .26                            
  \<7                                                         1.24 (0.85‐1.79)                                     
  Karnofsky PS                                                                                                     
  \>80                                                        1.00                  \<.01                   1.00   .78
  [\<]{.ul}80                                                 2.26 (1.55‐3.32)      1.07 (0.66‐1.75)               
  Neutrophil : lymphocyte ratio                                                                                    
  \<2.3                                                       1.00                  *\<.01*                 1.00   .03
  [\>]{.ul}2.3                                                2.05 (1.39‐3.04)      1.70 (1.04‐2.82)               
  Hemoglobin level \< LLN                                                                                          
  No                                                          1.00                  *.01*                   1.00   .15
  Yes                                                         1.80 (1.15‐2.95)      1.54 (0.86‐2.93)               
  Platelet count \> ULN                                                                                            
  No                                                          1.00                  .16                            
  Yes                                                         1.30 (0.90‐1.90)                                     
  Albumin level                                                                                                    
  [\>]{.ul}3.7 g/dL                                           1.00                  *\<.01*                 1.00   .05
  \<3.7 g/dL                                                  2.45 (1.67‐3.64)      1.72 (0.99‐3.02)               
  High calcium level                                                                                               
  No                                                          1.00                  .04                     1.00   .95
  Yes                                                         2.10 (1.03‐3.84)      0.97 (0.32‐2.35)               
  LDH level \>1.5× ULN                                                                                             
  No                                                          1.00                  .14                            
  Yes                                                         1.33 (0.91‐1.95)                                     
  CRP level                                                                                                        
  [\<]{.ul}0.7 mg/dL                                          1.00                  *\<.01*                 1.00   .94
  \>0.7 mg/dL                                                 2.21 (1.49 −3.30)     1.02 (0.60‐1.76)               

Abbreviations: CI, confidence interval; CRP, C reactive protein; HR, hazard ratio; LLN, lower limit of normal; PS, performance status; TKI, tyrosine kinase inhibitor; ULN, upper limit of normal.
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![Kaplan‐Meier curves of overall survival (OS) for the model‐development cohort (n = 242) of patients with metastatic renal cell carcinoma treated with axitinib, stratified using the new axitinib treatment prediction model. The median OS of the favorable, intermediate, and poor risk groups were not reached (NR) (95% confidence interval \[CI\], 50--NR), 29 (95% CI, 19‐50) months, and 11 (95% CI, 9‐15) months, respectively](CAS-111-2460-g003){#cas14449-fig-0003}

In the validation cohort (n = 243), 79 (36.7%), 60 (27.9%), and 76 (35.7%) patients were assigned to the favorable, intermediate, and poor risk groups, respectively. Figure [4](#cas14449-fig-0004){ref-type="fig"} shows the Kaplan‐Meier curves for these 3 risk groups in the validation cohort. The median OS of the favorable, intermediate, and poor risk groups were NR (95% CI, 50--NR), 27 (95% CI, 19‐45) months, and 14 (95% CI, 12‐21) months, respectively (*P* \< .001).

![Kaplan‐Meier curves of overall survival (OS) for the validation cohort (n = 243) of patients with metastatic renal cell carcinoma treated with axitinib, stratified using the axitinib treatment prediction model. The median OS of the favorable, intermediate, and poor risk groups were not reached (NR) (95% confidence interval \[CI\], 50--NR), 27 (95% CI, 19‐45) months, and 14 (95% CI, 12‐21) months, respectively](CAS-111-2460-g004){#cas14449-fig-0004}

Figure [5](#cas14449-fig-0005){ref-type="fig"} shows the Kaplan‐Meier curves of OS for all subjects stratified according to the ATP model and IMDC model, respectively. In addition, the median OS values according to the 2 systems are shown in Figure [5](#cas14449-fig-0005){ref-type="fig"}. The application of the ATP risk system to the patients that had been stratified according to the IMDC model led to the reclassification of 126 (54.1%) patients. The intermediate risk group accounted for 28.8% and 67.0% of all patients in the ATP model and IMDC model, respectively.

![Kaplan‐Meier curves of overall survival (OS) for the entire study population of patients with metastatic renal cell carcinoma treated with axitinib, stratified using (A) axitinib treatment prediction (ATP) model and (B) International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The median OS of the favorable, intermediate, and poor risk groups were not reached (NR) (95% confidence interval \[CI\], 58--NR), 27 (95% CI, 21‐42) months, and 13 (95% CI, 11‐15) months by ATP risk stratification. The median OS of the favorable, intermediate, and poor risk groups were 64 (95% CI, 44--NR), 35 (95% CI, 28‐50) months, and 13 (95% CI, 9‐15) months by IMDC risk stratification](CAS-111-2460-g005){#cas14449-fig-0005}

To analyze the accuracy of the OS predictions after the initiation of axitinib treatment, AUC values were calculated for each model (Figure [6](#cas14449-fig-0006){ref-type="fig"}). The adjusted AUC values at 12, 36, and 60 months after the initiation of axitinib were 0.77, 0.82, and 0.82, respectively, for the ATP model, and 0.69, 0.67, and 0.56, respectively, for the IMDC model. Thus, the longer the follow‐up period was, the more precisely the ATP model predicted prognosis when it was compared with IMDC risk model. In addition, this risk model can also be used to stratify patients into favorable, intermediate, and poor prognosis groups for estimating PFS. The median PFS of the patients with favorable, intermediate, and poor prognoses were 25, 15, and 8 months, respectively (Figure [S1](#cas14449-sup-0001){ref-type="supplementary-material"}). The therapies the patients received following axitinib are shown in Table [S6](#cas14449-sup-0007){ref-type="supplementary-material"}.

![Comparison of trends in the area under the curve (AUC) values of time‐dependent receiver operating characteristic (ROC) curves (prognostic performance) among the axitinib treatment prediction (ATP) model (disease stage at diagnosis, number of metastatic sites at the start of axitinib therapy, serum albumin level, and neutrophil : lymphocyte ratio) and International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) model. The adjusted AUC values at 12, 36, and 60 mo after the initiation of axitinib were 0.77, 0.82, and 0.82, respectively, for the ATP model, and 0.69, 0.67, and 0.56, respectively, for the IMDC model](CAS-111-2460-g006){#cas14449-fig-0006}

4. DISCUSSION {#cas14449-sec-0009}
=============

This study focused on patients that were treated with axitinib after 1 or 2 VEGFR‐TKI regimens. The clinical outcomes of these patients were reported, and a new prognostic model for these patients was developed. The median OS of all patients was 34 months, which was comparable with the findings of previous reports (Table [S3](#cas14449-sup-0004){ref-type="supplementary-material"}). In addition, we identified potential prognostic factors for OS, that is, the neutrophil : lymphocyte ratio, serum albumin level, the number of metastases at diagnosis, and the disease stage at diagnosis. Patients that did not show any of these adverse prognostic factors experienced a long‐term benefit from axitinib as a second‐line or subsequent treatment and showed favorable OS. These findings indicate that axitinib is still active and well tolerated as a second‐line or subsequent treatment among metastatic renal cell carcinoma patients that were previously treated with VEGFR‐TKI monotherapy.

The results of the present study were comparable with those of the large‐cohort AXIS trial. In the current study and the AXIS trial, the median OS of the study population was 34.0 and 20.1 months, respectively, the median PFS was 14.0 and 6.7 months, respectively, and the ORR was 22.8% and 23.0%, respectively.[^3^](#cas14449-bib-0003){ref-type="ref"}, [^5^](#cas14449-bib-0005){ref-type="ref"} The median duration of axitinib treatment was slightly longer (9.0 months) in the present study than in the AXIS trial (8.2 months). Regarding the median OS, our result was comparable with those of other retrospective cohort studies (median OS, 15.5‐29.5 months).[^6^](#cas14449-bib-0006){ref-type="ref"}, [^8^](#cas14449-bib-0008){ref-type="ref"}, [^9^](#cas14449-bib-0009){ref-type="ref"} Interestingly, the median OS and PFS values reported in Asian countries were longer than those reported in Europe and North America, despite both groups showing similar ORR (Table [S3](#cas14449-sup-0004){ref-type="supplementary-material"}). Some of the possible reasons for this include racial differences and differences in health insurance systems.[^18^](#cas14449-bib-0018){ref-type="ref"} As reported elsewhere, the clinical response to axitinib therapy was not dependent on the type of first‐line VEGFR‐TKI therapy given for metastatic renal cell carcinoma.[^9^](#cas14449-bib-0009){ref-type="ref"} In addition, no significant differences in the effects of treatment were observed between the second‐line or third‐line settings. This could be due to the low statistical power of this study cohort.

Although direct comparison might be difficult, the target cohort of this retrospective study is similar to that of the Checkmate 025 trial, in which nivolumab was compared with everolimus. The proportions of the patients that were treated with axitinib after 1 and 2 VEGFR‐TKIs in the present study were 87% and 13%, respectively. These values are similar to those seen in the Checkmate 025 study (83% and 17%, respectively). Even though patients who received subsequent immune checkpoint inhibitor treatment were censored in this trial, the patients that were assigned to the favorable and intermediate risk groups displayed better OS (favorable, 64 \[44--NR\] months; intermediate, 34 \[28‐50\] months) (Figure [5](#cas14449-fig-0005){ref-type="fig"}) compared with the patients in the Checkmate 025 trial (favorable, NR; intermediate, 21.8 \[18.3--NR\] months). Our findings support the idea that selected metastatic renal cell carcinoma patients with favorable prognoses can benefit from axitinib, as the patients with favorable and intermediate risk disease showed comparable OS to the patients that were treated with nivolumab in the Checkmate 025 study.

The most common AEs of grade 3 or higher, or that led to dose reduction or treatment interruption, were diarrhea, fatigue, proteinuria, a decreased appetite, and hand‐foot syndrome. Although the most common AE (any grade) in the AXIS trial was hypertension, hypertension was the seventh most common AE in the present study. One of the reasons for this was that blood pressure was appropriately managed, and axitinib was not interrupted or discontinued due to hypertension in the current study. The other reason was that the initial dose of axitinib was carefully reduced in 17% of patients in this real‐world setting. The fact that axitinib has a short half‐life, which allows patients to easily recover from AEs if the drug is discontinued, and an acceptable toxicity profile support the selection of axitinib as a subsequent therapy for metastatic renal cell carcinoma after VEGFR‐TKI therapy.[^1^](#cas14449-bib-0001){ref-type="ref"}

All 4 of the prognostic factors identified in the present study, the neutrophil : lymphocyte ratio,[^19^](#cas14449-bib-0019){ref-type="ref"}, [^20^](#cas14449-bib-0020){ref-type="ref"} the serum albumin level,[^21^](#cas14449-bib-0021){ref-type="ref"} the disease stage at diagnosis,[^22^](#cas14449-bib-0022){ref-type="ref"} and the number of metastatic sites,[^23^](#cas14449-bib-0023){ref-type="ref"} have already been reported in the first‐line treatment setting. In particular, the neutrophil : lymphocyte ratio and serum albumin level are both recognized as inflammatory markers. As reported previously, the serum albumin level was one of the Glasgow prognostic factors.[^24^](#cas14449-bib-0024){ref-type="ref"} Recently, the neutrophil : lymphocyte ratio was reported to be associated with the prognosis of metastatic renal cell carcinoma patients that were treated with VEGFR‐TKI or immune checkpoint inhibitors.[^25^](#cas14449-bib-0025){ref-type="ref"}, [^26^](#cas14449-bib-0026){ref-type="ref"}, [^27^](#cas14449-bib-0027){ref-type="ref"} Regarding the prognostic factors for subsequent therapy for metastatic renal cell carcinoma, the neutrophil : lymphocyte ratio,[^28^](#cas14449-bib-0028){ref-type="ref"} serum albumin level,[^29^](#cas14449-bib-0029){ref-type="ref"} serum LDH level,[^29^](#cas14449-bib-0029){ref-type="ref"} serum CRP level,[^28^](#cas14449-bib-0028){ref-type="ref"}, [^29^](#cas14449-bib-0029){ref-type="ref"}, [^30^](#cas14449-bib-0030){ref-type="ref"} and platelet : lymphocyte ratio[^28^](#cas14449-bib-0028){ref-type="ref"} have been identified as prognostic markers. However, the model‐development cohorts for these studies consisted of heterogenous populations, which included patients that had received a variety of treatments, including VEGFR‐TKIs and mTOR inhibitors. Some previous studies that focused on the subsequent treatment of metastatic renal cell carcinoma with axitinib identified the serum CRP level,[^8^](#cas14449-bib-0008){ref-type="ref"} prior nephrectomy,[^6^](#cas14449-bib-0006){ref-type="ref"} age at the time of diagnosis, clear cell histology, and the number of metastatic sites[^7^](#cas14449-bib-0007){ref-type="ref"} as significant predictors of OS.

One of the advantages of the present risk model is its objectivity. Unlike other conventional risk models, such as the IMDC risk model,[^11^](#cas14449-bib-0011){ref-type="ref"} the present risk model does not include subjective PS variables. Another advantage is that almost equal proportions of the study population were assigned to the favorable, intermediate, and poor risk groups by the present ATP risk model. As previously reported, it was pointed out by some of the authors that the conventional risk models assign more than half of patients to the intermediate risk group.[^20^](#cas14449-bib-0020){ref-type="ref"}, [^31^](#cas14449-bib-0031){ref-type="ref"} Therefore, they tried to optimize the conventional risk models so that they would assign patients to the intermediate risk group more precisely, according to their actual prognoses.[^20^](#cas14449-bib-0020){ref-type="ref"}, [^31^](#cas14449-bib-0031){ref-type="ref"} As far as we are aware, this is the first risk model developed using a study population that had all received axitinib after 1 or 2 VEGFR‐TKI regimens.

Our study is limited by its retrospective design, selection bias, unmeasured confounding factors, changes in clinical practice patterns over time, and the fact that the cohort was previously treated with VEGFR‐TKI monotherapy before the immunotherapy era. Currently, all patients are candidates for first‐line immunotherapy including axitinib plus avelumab, axitinib plus pembrolizumab, and nivolumab plus ipilimumab. Although CR rates of the IO drug/VEGFR‐TKI combination therapy or IO/IO combination therapy are higher than that of VEGFR‐TKI monotherapy, they are still approximately 10%. Accordingly, sequential therapy still plays an important role in improving OS for patients with metastatic renal cell carcinoma. In this viewpoint, this study provides additional data that will help clinicians to identify patients with metastatic renal cell carcinoma who would obtain a long‐term benefit from axitinib. Although further studies with a cohort that was treated with IO therapy and longer follow‐up times will be needed to validate our model, we expect that the ATP model will be a clinically valuable tool for the risk stratification of first‐line or further‐line treatment. In the future, analysis of gene expression signatures and further refinement of prognostic biomarkers will enable us to precisely decide optimal treatment regimens for patients.

The results of the present study suggest that 4 factors, the neutrophil : lymphocyte ratio, the serum albumin level, the disease stage at diagnosis, and the number of metastatic sites at the start of axitinib treatment, were identified as potential prognostic factors for OS among metastatic renal cell carcinoma patients that are treated with axitinib in the subsequent treatment setting. Patients without any of these prognostic factors would be assigned to the favorable risk group and would be expected to show favorable OS when treated with axitinib.
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